One Shot, Five Organs: FGF21 Gene Therapy Extends Mouse Healthspan by 20%
BiohackingA single injection extended median mouse lifespan by more than 20% — and it was administered after age-related decline had already set in.
What Happened
A research team led by Professor Fátima Bosch at the Universitat Autònoma de Barcelona, supported by Kriya Therapeutics, published results in Molecular Therapy showing that a single intramuscular injection of an adeno-associated virus (AAV) encoding the metabolic hormone FGF21 significantly extended healthspan and lifespan in naturally aged mice. Treatment began in animals aged 13 to 22 months — the equivalent of late middle age in human terms — after age-related decline was already observable.
Why It Matters
The five-organ outcome is what distinguishes this study. FGF21 regulates how the body burns and stores fuel, maintaining metabolic balance across muscle, liver, fat, and brain. The AAV delivery enabled persistent hormone expression from a single dose, producing measurable improvements across the liver, kidneys, heart, skeletal muscle, and brain simultaneously. The mice showed improved insulin sensitivity, reduced body weight and adiposity, enhanced muscle strength and endurance, better cognitive performance, and prevention of cardiac and renal fibrosis.
That the treatment worked in already-aged animals matters for clinical translation. Most longevity studies test interventions in young or middle-aged animals, which sets up a category error: the relevant question for most people is whether a therapy can slow aging that has already started, not whether it can prevent aging from starting. The Barcelona team’s decision to begin treatment post-decline puts the result closer to the question humans actually need answered.
The broader significance is that FGF21’s mechanisms appear to be systemic rather than organ-specific. Previous research had established FGF21’s role in metabolic regulation; this study suggests that sustained elevation of the hormone in aged tissue produces multi-organ benefits simultaneously, which is a different claim than localized organ protection.
The So What
Single-dose gene therapies for aging are not a near-term clinical reality for humans. The path from a mouse study in Molecular Therapy to an approved therapy in humans spans years of toxicology work, dose-finding trials, and regulatory review. What this study contributes is a mechanistic signal: FGF21 delivered persistently via AAV reaches multiple organ systems with a consistent protective effect in aged animals, including after decline has begun. That finding makes FGF21 a more credible candidate for human longevity research than many predecessors, and it gives researchers at Kriya Therapeutics and similar groups a well-characterized starting point for translation work.
Source: Longevity.Technology
Content created with AI assistance and reviewed for accuracy.
Join the conversation
Stack Insiders is our free community for readers who want to go deeper — share resources, ask questions, and connect with others across every vertical we cover.
Join Stack Insiders →